About
About IBEX Technologies Inc
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada. As of April 8, 2024, IBEX Technologies Inc. operates as a subsidiary of BBI Solutions OEM Limited.
Visit company website
5 years, 5 months ago
IBEX Technologies Inc is currently in a long term uptrend where the price is trading 1.5% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
IBEX Technologies Inc's total revenue rose by 30.7% to $1M since the same quarter in the previous year.
Its net income has increased by 956.8% to $249K since the same quarter in the previous year.
Finally, its free cash flow fell by 146.0% to $-259K since the same quarter in the previous year.
Based on the above factors, IBEX Technologies Inc gets an overall score of 4/5.